1. Acknowledgement to Referees

   Acknowledgement to Referees 29 October 2018 Pages: 539 - 542

2. Anakinra in Still’s disease: a profile of its use

   • Katherine A. Lyseng-Williamson

   Adis Drug Q&A Open access 31 October 2018 Pages: 543 - 553

3. Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA

   • Hannah A. Blair

   Adis Drug Q&A 13 November 2018 Pages: 554 - 559

4. Lesinurad in hyperuricaemia of gout: a profile of its use in the EU

   • Hannah A. Blair
   • Emma D. Deeks

   Adis Drug Q&A 09 October 2018 Pages: 560 - 566

   

5. Additional non-invasive options can be considered for erectile dysfunction when phosphodiesterase type 5 inhibitors fail

   • Adis Medical Writers

   Disease Management 06 September 2018 Pages: 567 - 571

6. First reports of adverse drug reactions

   Drug Reactions and Interactions 09 November 2018 Pages: 572 - 572

7. Pharmacist perspectives towards pharmaceutical care services in neonatal intensive care units in Australia and Poland

   • Natalia Krzyżaniak
   • Iga Pawłowska
   • Beata Bajorek

   Original Research Article 18 September 2018 Pages: 573 - 582

8. Knowledge and consumption of emergency contraception pills in a tertiary education student population

   • João Joaquim
   • Marlene Reis
   • Timóteo Pires

   Original Research Article 19 September 2018 Pages: 583 - 589

   

9. A new complication of imatinib: a case report

   • Sushila Chauhan
   • Sunil Anand

   Short Communication 27 September 2018 Pages: 590 - 592

   

10. Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA

    • Young-A Heo

    Correction Open access 17 November 2018 Pages: 593 - 593

11. Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA

    • Kate McKeage
    • Katherine A. Lyseng-Williamson

    Correction Open access 16 November 2018 Pages: 594 - 594

12. Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA

    • Katherine A. Lyseng-Williamson

    Correction Open access 12 November 2018 Pages: 595 - 595

13. Correction to: Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT^®) in attention-deficit hyperactivity disorder: a profile of their use

    • Katherine A. Lyseng-Williamson

    Correction 12 October 2018 Pages: 596 - 596